Home › Products & Services › Pharmaprojects+
Every asset from preclinical to launch, including failed and withdrawn drugs, continuously updated by specialist analysts.
Benchmark active pipelines, map mechanism saturation, and surface non-obvious competitors in seconds
Ask complex pipeline questions and get structured, evidence-backed answers drawn from Pharmaprojects+ data.
Benchmark any company’s pipeline and see where the market is heading.
See which companies, therapies, mechanisms, and indications are advancing, and how the competitive landscape is evolving.
Surface underserved indications, emerging mechanisms, and portfolio gaps early, backed by 40+ years of curated pipeline history.
Move beyond a static view of the pipeline with the context to evaluate opportunities, prioritise investment, and decide where to compete next.

Every asset from preclinical to launch, curated and enriched by expert analysts.

Filter across 3,700+ mechanisms and 1,100+ targets by stage, modality, geography and more.

Spot discontinued assets worth in-licensing and map mechanism saturation to find white space.

Dedicated rare disease coverage: orphan drug designations, program status, and sponsor information.

Unlimited access to Citeline's analysts, with rapid response times.

Move from pipeline to trial design to site selection without switching platforms.
| Capability | Other pipeline databases | Pharmaprojects+ |
|---|---|---|
| Global drug pipeline coverage | ||
| Search and filtering by indication and phase | ||
| Expert-curated records, not scraped data | ||
| 40+ years of historical pipeline data with annual snapshots | ||
| Coverage of failed and withdrawn assets | ||
| Company Compare: active pipeline benchmarking side by side | ||
| Drug Similarity: chemical, biologic, and mechanistic comparators | ||
| Advanced Analytics: pipeline by mechanism, modality, and geography | ||
| AI-powered search and analysis with Ella | ||
| Direct access to expert analysts via Ask the Analyst |
Benchmark active pipelines side by side and surface the non-obvious competitors around any asset.